Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on T cell-redirecting cancer immunotherapies, has announced upcoming presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer in Houston, Texas from November 6-10, 2024. The company will deliver two oral presentations and five poster presentations.
The oral presentations will cover:
- ACTengine IMA203 TCR-T targeting PRAME, showing deep and durable anti-tumor activity in heavily pretreated solid cancer patients
- Enhanced pharmacology data of next-generation IMA203CD8 TCR-T monotherapy targeting PRAME
The poster presentations will address various topics including T cell persistence monitoring, allogeneic γδ T cell production, PRAME-targeting therapies, and TCR-engineered T cells with enhanced persistence.
Immatics N.V. (NASDAQ: IMTX), una compagnia biofarmaceutica in fase clinica focalizzata sulle immunoterapie oncologiche che riconducono le cellule T, ha annunciato presentazioni in arrivo al 39° Congresso Annuale della Società per l'Immunoterapia del Cancro che si terrà a Houston, Texas, dal 6 al 10 novembre 2024. L'azienda presenterà due presentazioni orali e cinque presentazioni poster.
Le presentazioni orali copriranno:
- ACTengine IMA203 TCR-T che colpisce PRAME, mostrando un'attività antitumorale profonda e duratura in pazienti con tumori solidi fortemente pretrattati
- Dati di farmacologia potenziati della terapia monologica di IMA203CD8 TCR-T di nuova generazione che colpisce PRAME
Le presentazioni poster tratteranno vari argomenti, tra cui il monitoraggio della persistenza delle cellule T, la produzione di cellule T γδ allogeniche, le terapie mirate a PRAME e le cellule T ingegnerizzate con TCR con persistenza potenziata.
Immatics N.V. (NASDAQ: IMTX), una compañía biofarmacéutica en etapa clínica centrada en las inmunoterapias contra el cáncer que redirigen las células T, ha anunciado presentaciones que se llevarán a cabo en el 39° Congreso Anual de la Sociedad para la Inmunoterapia del Cáncer en Houston, Texas, del 6 al 10 de noviembre de 2024. La compañía presentará dos presentaciones orales y cinco presentaciones en póster.
Las presentaciones orales abarcarán:
- ACTengine IMA203 TCR-T dirigido a PRAME, mostrando una profunda y duradera actividad antitumoral en pacientes con cáncer sólido altamente pretratado
- Datos farmacológicos mejorados de la terapia monológica IMA203CD8 TCR-T de nueva generación dirigida a PRAME
Las presentaciones en póster abordarán varios temas, incluyendo el monitoreo de la persistencia de células T, la producción de células T γδ alogénicas, terapias dirigidas a PRAME y células T con TCR ingenierizadas con mayor persistencia.
Immatics N.V. (NASDAQ: IMTX)는 T 세포 리디렉션을 통한 암 면역 치료에 초점을 맞춘 임상 단계의 생명공학 회사로, 2024년 11월 6일부터 10일까지 텍사스 휴스턴에서 열리는 제39회 암 면역요법 학회 연례 회의에서 다가오는 발표를 발표했습니다. 이 회사는 두 개의 구두 발표와 다섯 개의 포스터 발표를 진행할 예정입니다.
구두 발표는 다음 내용을 다룰 것입니다:
- PRAME을 표적으로 하는 ACTengine IMA203 TCR-T로, 중증 미리 치료된 고형 암 환자에서 깊고 지속적인 항종양 활성을 보여줌
- PRAME을 표적으로 하는 차세대 IMA203CD8 TCR-T 단일요법의 향상된 약리학 데이터
포스터 발표에서는 T 세포 지속성 모니터링, 이종 γδ T 세포 생산, PRAME 표적 치료, 내구성 증대된 TCR 엔지니어링 T 세포 등 다양한 주제를 다룰 것입니다.
Immatics N.V. (NASDAQ: IMTX), une société biopharmaceutique en phase clinique spécialisée dans les immunothérapies anticancéreuses redirigeant les cellules T, a annoncé de prochaines présentations lors du 39ème Congrès Annuel de la Société pour l'Immunothérapie du Cancer à Houston, Texas, du 6 au 10 novembre 2024. La société présentera deux présentations orales et cinq présentations poster.
Les présentations orales porteront sur :
- ACTengine IMA203 TCR-T ciblant PRAME, montrant une activité antitumorale profonde et durable chez les patients atteints de cancer solide fortement prétraités
- Données pharmacologiques améliorées de la monothérapie IMA203CD8 TCR-T de nouvelle génération ciblant PRAME
Les présentations poster aborderont divers sujets, y compris le suivi de la persistance des cellules T, la production de cellules T γδ allogéniques, les thérapies ciblant PRAME et les cellules T transformées par TCR avec une persistance améliorée.
Immatics N.V. (NASDAQ: IMTX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf T-Zell-redirecting Krebsimmuntherapien spezialisiert hat, hat bevorstehende Präsentationen auf dem 39. Jährlichen Treffen der Gesellschaft für Immuntherapie von Krebs in Houston, Texas, vom 6. bis 10. November 2024 angekündigt. Das Unternehmen wird zwei mündliche Präsentationen und fünf Posterpräsentationen halten.
Die mündlichen Präsentationen werden folgende Themen behandeln:
- ACTengine IMA203 TCR-T, das PRAME anvisiert, zeigt tiefe und dauerhafte antitumorale Aktivität bei stark vorbehandelten Patienten mit soliden Tumoren
- Verbesserte Pharmakologiedaten der monotherapeutischen IMA203CD8 TCR-T der nächsten Generation, die PRAME anvisiert
Die Posterpräsentationen werden verschiedene Themen ansprechen, einschließlich Monitoring der T-Zell-Persistenz, allogene γδ T-Zellproduktion, PRAME-zielgerichtete Therapien und TCR-ingenieurierte T-Zellen mit verbesserter Persistenz.
- Immatics is presenting multiple studies at a major cancer immunotherapy conference, demonstrating active research and development
- The company's IMA203 TCR-T therapy targeting PRAME shows deep and durable anti-tumor activity in heavily pretreated solid cancer patients
- Immatics is advancing next-generation IMA203CD8 TCR-T monotherapy with enhanced pharmacology data
- None.
Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming oral and poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer in Houston, Texas from November 6 - 10, 2024.
Full abstracts will be available on November 5, 2024, at 9:00 am EST in the JITC Supplement.
Oral Presentations
Date / Time: November 8, 2024 / 3:50 – 5:25 pm Central Standard Time
Session: Oral Abstract Session 1
Abstract Number: 687
Title: ACTengine IMA203 TCR-T targeting PRAME shows deep and durable anti-tumor activity in heavily pretreated solid cancer patients
Presenter: Martin Wermke, M.D. (University Hospital Dresden, Germany)
Date / Time: November 9, 2024 / 12:30 PM - 1:30 pm Central Standard Time
Session: Rapid Oral - Clinical 2
Abstract Number: 661
Title: Enhanced pharmacology data of next-generation IMA203CD8 TCR-T monotherapy targeting PRAME
Presenter: Dejka M. Araujo, M.D. (MD Anderson Cancer Center, Houston, Texas, USA)
Poster Presentations
Date: November 8, 2024
Poster Number: 355
Title: An approach to bridging starting materials to monitor T cell persistence in adoptive T cell therapy
Presenter: Jourdan Andersson, Ph.D. (Immatics)
Date: November 9, 2024
Poster Number: 226
Title: An effective donor screening program for manufacturing of allogeneic γδ T cell products
Presenter: Inbar Azoulay Alfaguter, Ph.D. (Immatics)
Date: November 9, 2024
Poster Number: 228
Title: Optimizing and streamlining the manufacturing of Vγ9Vδ2 γδ T cells for allogeneic therapy
Presenter: Pooja Mehta, Ph.D. (Immatics)
Date: November 9, 2024
Abstract Number: 360
Title: Combination of a TCR-engineered autologous PRAME-targeting T cell therapy with a PRAME-encoding mRNA for the treatment of solid tumors
Presenter: Fabian Brunk, Ph.D. (Immatics)
Date: November 9, 2024
Poster Number: 372
Title: TCR-engineered T cells exhibit enhanced persistence and serial killing ability when armored with membrane-bound IL-15
Presenter: Justin Gunesch, Ph.D. (Immatics)
About IMA203 and Target PRAME
ACTengine® IMA203 T cells are directed against an HLA-A*02-presented peptide derived from preferentially expressed antigen in melanoma (PRAME), a protein frequently expressed in a large variety of solid cancers, thereby supporting the program’s potential to address a broad cancer patient population. Immatics’ PRAME peptide is present at a high copy number per tumor cell and is homogeneously and specifically expressed in tumor tissue. The peptide has been identified and characterized by Immatics’ proprietary mass spectrometry-based target discovery platform, XPRESIDENT®. Through its proprietary TCR discovery and engineering platform XCEPTOR®, Immatics has generated a highly specific T cell receptor (TCR) against this target for its TCR-based cell therapy approach, ACTengine® IMA203.
ACTengine® IMA203 TCR-T is currently being evaluated in Phase 1 IMA203 monotherapy, and IMA203CD8 (GEN2) monotherapy, where IMA203 engineered T cells are co-transduced with a CD8αβ co-receptor.
About Immatics
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates you can also follow us on X, Instagram and LinkedIn.
For more information, please contact:
| Media | |
| Trophic Communications | |
| Phone: +49 171 3512733 | |
| immatics@trophic.eu |
| Immatics N.V. | |
| Jordan Silverstein | |
| Head of Strategy | |
| Phone: +1 346 319-3325 | |
| InvestorRelations@immatics.com |
Attachment
FAQ
What is the date and location of the Society for Immunotherapy of Cancer Annual Meeting 2024 where Immatics (IMTX) will present?
How many oral presentations will Immatics (IMTX) deliver at the SITC 2024 conference?
What is the main focus of Immatics' (IMTX) ACTengine IMA203 TCR-T therapy presentation at SITC 2024?
How many poster presentations will Immatics (IMTX) have at the SITC 2024 conference?
